Cabotegravir/rilpivirine

From IDWiki
Revision as of 21:17, 1 April 2023 by Aidan (talk | contribs) (Created page with "* Long-acting injectable medication used to treat HIV * Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary * Dosing ** 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks ** 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks ** Can be given ±1 week of target date ** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything) * Injectio...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
  • Long-acting injectable medication used to treat HIV
  • Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary
  • Dosing
    • 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks
    • 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks
    • Can be given ±1 week of target date
    • If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)
  • Injections
    • May need long needle to reach muscle in obese patients
    • Often given as rilpivirine into right buttock and cabotegravir into left
  • Virologic failures
    • Occur despite perfect adherence
    • Increased if rilpivirine RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI
  • Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection
    • Use with caution if risk factors for virologic failure; may warrant closer monitoring